Pipeline Therapeutics and Janssen partner for neuroscience therapy
2023-04-19
临床1期引进/卖出临床2期
Preview
来源: Pharmaceutical Technology
Photomicrograph of a demyelinating multiple sclerosis lesion. Credit: Marvin 101 / commons.wikimedia.org.
Pipeline Therapeutics and Janssen Pharmaceutical have signed a global licence and development agreement for PIPE-307 to treat disorders of the nervous system.
An oral, selective, muscarinic M1 receptor antagonistmuscarinic M1 receptor antagonist, PIPE-307, has been designed to drive oligodendrocyte precursor cells’ mutations into oligodendrocytes that produce myelin.
PIPE-307 has already been evaluated in two Phase I clinical trials in healthy patients, and has also received Food and Drug Administration (FDA) clearance as an investigational new drug (IND) to commence its clinical development in patients with relapsing-remitting multiple sclerosis (RRMS).
Upon completion of the transaction, Pipeline will also receive an equity investment of up to $25m separately from Johnson & Johnson Innovation, as well as up to $25m in equity investments from the existing investors of the company.
Pipeline will receive $1bn in clinical, regulatory and commercial milestones, along with royalty payments.
Pipeline president and CEO Carmine Stengone said: “We are excited to announce this agreement, which is aligned with our vision to maximise the reach of PIPE-307 through clinical evaluation in RRMS and other neurological disorders.
“In addition, we are pleased that we will strengthen our financial position with the upfront payment from this agreement and equity investments from existing and new investors, enabling us to extend our runway and to continue advancing our portfolio in small molecule neuroregeneration.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。